Viswanadhan Krishnan 4

What Happened
Viswanadhan Krishnan, Chief of Corporate Development & Strategy at Agios Pharmaceuticals (AGIO), was granted two derivative awards on March 1, 2026: 14,000 restricted stock units (RSUs) and an award covering 52,000 shares (option). Both awards show $0 cash paid at grant (standard for grants); the reported dollar value at grant is $0 on the Form 4 (intrinsic/exercise price not shown in the items provided).

Key Details

• Transaction date: March 1, 2026; Form 4 filed March 3, 2026 (filed within the two-business-day window).
• Reported price: $0.00 for both grants (award/grant reporting, not an open‑market purchase).
• Share counts: 14,000 RSUs; 52,000 option shares awarded.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnotes:
  • F1: Each RSU represents a contingent right to receive one share of common stock.
  • F2: The RSUs vest beginning March 1, 2027 in three equal annual installments.
  • F3: The option vests 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments.
• Filing timeliness: Reported March 3, 2026 — appears timely under Form 4 rules.

Context
These are grant-type (derivative) awards, not open-market purchases or sales. RSUs convert to shares only when they vest; the option award must be exercised (and may carry an exercise price and tax implications) before any shares are received. Because no shares were sold or bought on the open market, this filing reports compensation grants rather than a direct bullish or bearish trading signal.